DK3319643T3 - HBED-bisphosphonater og radiometalkonjugater deraf, anvendelige som theranostiske midler - Google Patents
HBED-bisphosphonater og radiometalkonjugater deraf, anvendelige som theranostiske midler Download PDFInfo
- Publication number
- DK3319643T3 DK3319643T3 DK16821892.3T DK16821892T DK3319643T3 DK 3319643 T3 DK3319643 T3 DK 3319643T3 DK 16821892 T DK16821892 T DK 16821892T DK 3319643 T3 DK3319643 T3 DK 3319643T3
- Authority
- DK
- Denmark
- Prior art keywords
- hbed
- radiometal
- bisphosphonates
- conjugates
- useful
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title 1
- -1 HBED bisphosphonates Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
- C07F9/3817—Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Radiology & Medical Imaging (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189652P | 2015-07-07 | 2015-07-07 | |
| US201662320296P | 2016-04-08 | 2016-04-08 | |
| PCT/US2016/041040 WO2017007790A1 (en) | 2015-07-07 | 2016-07-06 | Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3319643T3 true DK3319643T3 (da) | 2020-06-15 |
Family
ID=57685907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16821892.3T DK3319643T3 (da) | 2015-07-07 | 2016-07-06 | HBED-bisphosphonater og radiometalkonjugater deraf, anvendelige som theranostiske midler |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10253052B2 (enExample) |
| EP (1) | EP3319643B1 (enExample) |
| JP (1) | JP6792875B2 (enExample) |
| KR (1) | KR102651945B1 (enExample) |
| CN (1) | CN107847618B (enExample) |
| AU (1) | AU2016289474C1 (enExample) |
| CA (1) | CA2991498A1 (enExample) |
| DK (1) | DK3319643T3 (enExample) |
| EA (1) | EA201890221A1 (enExample) |
| IL (1) | IL256726A (enExample) |
| MX (1) | MX377208B (enExample) |
| WO (1) | WO2017007790A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377208B (es) | 2015-07-07 | 2025-03-07 | Five Eleven Pharma Inc | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. |
| TW201832750A (zh) * | 2017-03-02 | 2018-09-16 | 美商５１１製藥公司 | 放射性藥品標記裝置 |
| WO2020028825A1 (en) * | 2018-08-03 | 2020-02-06 | Board Of Regents, The University Of Texas System | Method for extraction and purification of 68ga |
| CN109438517B (zh) * | 2018-12-27 | 2021-01-08 | 北京久杰净化工程技术有限公司 | 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法 |
| CA3137963A1 (en) * | 2019-04-26 | 2020-10-29 | Five Eleven Pharma Inc. | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents |
| WO2021067513A1 (en) * | 2019-10-01 | 2021-04-08 | City Of Hope | Metal chelating agents and methods of using the same |
| DE102021101216A1 (de) * | 2021-01-21 | 2022-07-21 | Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts | Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen |
| DE102022105175A1 (de) * | 2022-03-04 | 2023-09-07 | Atoms for Cure GmbH | Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik |
| CN119060093B (zh) * | 2024-08-26 | 2025-09-05 | 广州医科大学附属第一医院（广州呼吸中心） | 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用 |
| CN119060094B (zh) * | 2024-08-26 | 2025-09-05 | 广州医科大学附属第一医院（广州呼吸中心） | 一种靶向成纤维细胞激活蛋白的抑制剂类放射性探针及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE329623T1 (de) * | 2001-10-22 | 2006-07-15 | Dow Global Technologies Inc | Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium |
| EP1611119A1 (en) * | 2003-04-03 | 2006-01-04 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| US7161000B2 (en) * | 2003-05-30 | 2007-01-09 | Sumitomo Chemical Company, Limited | Method for producing phenol condensate |
| US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| CN104774175B (zh) * | 2007-06-26 | 2019-04-16 | 约翰·霍普金斯大学 | 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途 |
| JP5690733B2 (ja) * | 2009-08-20 | 2015-03-25 | 富士フイルムＲｉファーマ株式会社 | ビスホスホン酸誘導体及びその放射性金属核種標識体 |
| CN103459573B (zh) * | 2011-04-13 | 2015-11-25 | 弗门尼舍有限公司 | 用于控制加香醛和酮的释放的平衡动态混合物 |
| ITMI20121156A1 (it) | 2012-06-29 | 2013-12-30 | Consiglio Nazionale Ricerche | Metodo di elaborazione di immagini di tomografia a coerenza ottica |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| MX377208B (es) | 2015-07-07 | 2025-03-07 | Five Eleven Pharma Inc | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. |
-
2016
- 2016-07-06 MX MX2018000239A patent/MX377208B/es active IP Right Grant
- 2016-07-06 EA EA201890221A patent/EA201890221A1/ru unknown
- 2016-07-06 CN CN201680046397.5A patent/CN107847618B/zh active Active
- 2016-07-06 AU AU2016289474A patent/AU2016289474C1/en active Active
- 2016-07-06 WO PCT/US2016/041040 patent/WO2017007790A1/en not_active Ceased
- 2016-07-06 CA CA2991498A patent/CA2991498A1/en active Pending
- 2016-07-06 JP JP2017568376A patent/JP6792875B2/ja active Active
- 2016-07-06 KR KR1020187002872A patent/KR102651945B1/ko active Active
- 2016-07-06 DK DK16821892.3T patent/DK3319643T3/da active
- 2016-07-06 EP EP16821892.3A patent/EP3319643B1/en active Active
- 2016-07-06 US US15/203,602 patent/US10253052B2/en active Active
-
2018
- 2018-01-03 IL IL256726A patent/IL256726A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018524352A (ja) | 2018-08-30 |
| KR20180026736A (ko) | 2018-03-13 |
| MX377208B (es) | 2025-03-07 |
| US20170022224A1 (en) | 2017-01-26 |
| WO2017007790A9 (en) | 2018-01-04 |
| EP3319643A4 (en) | 2019-04-10 |
| CA2991498A1 (en) | 2017-01-12 |
| HK1254864A1 (en) | 2019-07-26 |
| EP3319643B1 (en) | 2020-04-22 |
| AU2016289474A1 (en) | 2018-02-01 |
| AU2016289474B2 (en) | 2020-12-24 |
| CN107847618A (zh) | 2018-03-27 |
| JP6792875B2 (ja) | 2020-12-02 |
| US10253052B2 (en) | 2019-04-09 |
| IL256726A (en) | 2018-03-29 |
| WO2017007790A1 (en) | 2017-01-12 |
| KR102651945B1 (ko) | 2024-03-26 |
| EP3319643A1 (en) | 2018-05-16 |
| AU2016289474C1 (en) | 2021-04-08 |
| EA201890221A1 (ru) | 2018-06-29 |
| CN107847618B (zh) | 2021-07-16 |
| MX2018000239A (es) | 2018-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268697A (en) | Formulations | |
| DK3319643T3 (da) | HBED-bisphosphonater og radiometalkonjugater deraf, anvendelige som theranostiske midler | |
| DK3688162T3 (da) | Formuleringer | |
| DK3579883T3 (da) | Pyrrolobenzodiazepin-antistofkonjugater | |
| DK3592393T3 (da) | Frigørbare konjugater | |
| EP3380126A4 (en) | ANTIBODY-ACTIVE CONJUGATES WITH BRANCHED LINKERS AND ASSOCIATED METHODS | |
| LT3525830T (lt) | Pirolbenzodiazepino konjugatai | |
| DK3347472T3 (da) | Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf. | |
| EP3313857A4 (en) | POLYMER-CYCLODEXTRIN LIPID CONJUGATES | |
| DK3307707T3 (da) | Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider | |
| MA50657A (fr) | Formulations de niraparib | |
| BR112016018521A2 (pt) | composição, e, kit. | |
| LT3544636T (lt) | Pirolobenzodiazepino-antikūno konjugatai | |
| LT3386954T (lt) | Dimeriniai kontrastiniai agentai | |
| EP3662112A4 (en) | QUICK COUPLER | |
| EP3655436C0 (en) | SERUM ALBUMIN BINDING PROTEINS | |
| DK3612537T3 (da) | Pyrrolobenzodiazepinkonjugater | |
| DK3377634T3 (da) | Bakteriebaseret proteinafgivelse | |
| EP3355931C0 (en) | PROTEIN CONJUGATES | |
| DK3078365T3 (da) | Solubiliseringsmidler og vandige sammensætninger omfattende disse | |
| DK2968083T3 (da) | Dental sammensætning, som omfatter chelator og base | |
| DK3608334T3 (da) | Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf | |
| FI20155191L (fi) | Nivel | |
| DK3326463T3 (da) | Midesammensætning og anvendelse deraf som biologisk bekæmpelsesmiddel | |
| MA50068A (fr) | Formulations de copanlisib |